See other companies on Welcome to the Jungle
Olema Oncology
Therapy development for women's cancers
- 21-100 employees
- Healthcare
- B2B
- Biology
- Science
- South Park, San Francisco, CA
Jump to section
Company mission
To develop therapies that offer the potential to improve outcomes for women living with cancer.
142% employee growth in 12 months
Our take
With the global oncology drug market expected to exceed $390 billion by 2027, there is a massive commercial opportunity in cancer research. Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers.
Olema are leveraging the knowledge of the molecular action of estrogen receptors, designing compounds that should be superior to both current drugs and those in development. It has secured massive amounts of funding, the latest of which will support its planned monotherapy Phase 3 trial, and will continue to advance research and development across other projects.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Annual bonus, and stock equity package
- 401K Match and the option to participate in an Employee Stock Purchase Plan
- Robust health plan for both our employees’ and their dependents’ medical, dental, and vision coverage
- Flexible work model
- Offices in San Francisco and Boston
- Allowances to help with both home office and commute
- Flexible Time Off Vacation package
Company values
- Collaboration
- Understanding
- Inclusion
Funding (2 rounds)
Jul 2020
$54m
SERIES B
Aug 2018
$6.1m
SERIES A
Total funding: $60.1m
This company has top investors
Leadership
Cyrus Harmon
(Member of the Board)CEO of computational biotechnology company Vilya. Earned a PhD in Molecular and Cell Biology from University of California, Berkeley. Previously VP of Computational Genomics at Affymetrix.
Peter Kushner
(Chief Scientific Officer)Earned a PhD in Molecular Biology from the University of Oregon. Has been a Professor Emeritus at the University of California since 1986.